Adequate organ function as defined per protocolXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate major organ functionXx_NEWLINE_xXNormal organ and marrow function:Xx_NEWLINE_xXAdequate hematologic and end-organ functionXx_NEWLINE_xXHave adequate organ function.Xx_NEWLINE_xXSubject has adequate organ and marrow function.Xx_NEWLINE_xXAcceptable laboratory parameters and adequate organ reserveXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXDemonstrate adequate organ function as defined below:Xx_NEWLINE_xX6. Adequate organ and marrow function;Xx_NEWLINE_xXAdequate hematologic and end organ functionXx_NEWLINE_xXAdequate hematologic and end-organ functionXx_NEWLINE_xXHas adequate organ functionXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXDemonstrate adequate organ function as evidenced by laboratory testingXx_NEWLINE_xXAdequate organ function as defined below:Xx_NEWLINE_xXAdequate organ function as indicated by laboratory valuesXx_NEWLINE_xXAdequate organ function per protocol-defined criteria.Xx_NEWLINE_xXAdequate organ function defined as follows:Xx_NEWLINE_xXAdequate end-organ functionXx_NEWLINE_xXHas adequate organ function.Xx_NEWLINE_xXAdequate hematologic and end organ function based on laboratory results obtained within 14 days prior to initiation of study treatment;Xx_NEWLINE_xXAdequate organ function at baseline .Xx_NEWLINE_xXAdequate hematologic and end-organ function, defined by laboratory test results, obtained within 14 days before initiation of study treatmentXx_NEWLINE_xXAdequate hematologic and end-organ functionXx_NEWLINE_xXPatient must meet the organ function and system function requirements as stated in the protocolXx_NEWLINE_xXAdequate organ and marrow functionXx_NEWLINE_xXAdequate organ and marrow functionXx_NEWLINE_xXAdequate organ function as measured by various blood parametersXx_NEWLINE_xXAdequate hematologic and end organ functionXx_NEWLINE_xXHave adequate organ function.Xx_NEWLINE_xXHave adequate organ function, defined as:Xx_NEWLINE_xXDemonstrates adequate organ functionXx_NEWLINE_xXMust have adequate organ and marrow functionXx_NEWLINE_xXAdequate organ function.Xx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXPatient must have adequate organ function as indicated by the following laboratory values independent of transfusion within 2 weeks:Xx_NEWLINE_xXAdequate hematologic and end-organ functionXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXHave adequate organ functionXx_NEWLINE_xXAdequate hematological and organ function as confirmed by laboratory valuesXx_NEWLINE_xXAdequate organ function (defined by the following parameters):Xx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXHave adequate organ function, including:Xx_NEWLINE_xXPatient with adequate organ functionsXx_NEWLINE_xXAdequate organ function defined as follows:Xx_NEWLINE_xXHave adequate organ function.Xx_NEWLINE_xXHave adequate organ function.Xx_NEWLINE_xXAdequate organ function as defined by and obtained within 28 days of starting treatment:Xx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate organ functionsXx_NEWLINE_xXPoor organ function.Xx_NEWLINE_xXDemonstrates adequate organ function.Xx_NEWLINE_xXAdequate organ function, defined as follows:Xx_NEWLINE_xXAdequate organ function.Xx_NEWLINE_xXSubjects with adequate organ and marrow functionXx_NEWLINE_xXAdequate hematologic and end-organ function Cancer-Related Inclusion Criteria:Xx_NEWLINE_xXAdequate hematologic and end-organ functionXx_NEWLINE_xXGood organ function:Xx_NEWLINE_xXAdequate organ function within 14 days of study registration (30 days for pulmonary and cardiac) as defined in section 4.5Xx_NEWLINE_xXAdequate hematologic and organ functionXx_NEWLINE_xXMust have adequate organ function.Xx_NEWLINE_xXDemonstrates adequate organ function.Xx_NEWLINE_xXAdequate hematologic and end-organ functionXx_NEWLINE_xXAdequate organ function as defined by the following laboratory values at screening:Xx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate hematologic and organ function within 28 days before the first study treatmentXx_NEWLINE_xXImpaired baseline organ function as evaluated by out-of-range laboratory valuesXx_NEWLINE_xXHas adequate organ functionXx_NEWLINE_xXPoor vital organ function defined as:Xx_NEWLINE_xXAdequate organ function defined as:Xx_NEWLINE_xXAdequate hematologic and end organ functionXx_NEWLINE_xXAdequate organ and marrow function as defined below:Xx_NEWLINE_xXHave adequate organ function.Xx_NEWLINE_xXHas adequate organ function.Xx_NEWLINE_xXHave adequate normal organ and marrow function, including the following:Xx_NEWLINE_xXAdequate organ function as determined by the following laboratory values:Xx_NEWLINE_xXThe patient has adequate organ and marrow function as follows:Xx_NEWLINE_xXOrgan Function Requirements:Xx_NEWLINE_xXAdequate organ function within 14 days of study registration including:\r\n* Platelets >= 100 x 10^9/LXx_NEWLINE_xXAdequate organ function within 14 days of study registration including:\r\n* Hemoglobin >= 8 g/dLXx_NEWLINE_xXOrgan function:Xx_NEWLINE_xXSubjects with adequate organ function as measured by:Xx_NEWLINE_xXAdequate hematologic and end organ functionXx_NEWLINE_xXPatients with organ dysfunctionXx_NEWLINE_xXadequate organ functionXx_NEWLINE_xXAdequate organ system function.Xx_NEWLINE_xXInadequate end organ function as defined by specified laboratory valuesXx_NEWLINE_xXPatients must have adequate major organ function and meet the following criteria:Xx_NEWLINE_xXInadequate performance status/organ function.Xx_NEWLINE_xXDemonstrate adequate organ functionXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXPatients who have poor organ function as defined by laboratory parameters specified in the protocol.Xx_NEWLINE_xXAdequate hematologic and end-organ functionXx_NEWLINE_xXAdequate baseline organ function within 14 days prior to the first dose of enzalutamide and/or CORT125281Xx_NEWLINE_xXORGAN FUNCTION AND PERFORMANCE STATUS CRITERIA:Xx_NEWLINE_xXInadequate performance status/organ function.Xx_NEWLINE_xXAdequate organ function at screeningXx_NEWLINE_xXHas adequate organ functionXx_NEWLINE_xXHas adequate organ function within 7 days before enrollmentXx_NEWLINE_xXPatients must have normal organ and marrow function as defined at the discretion of the treating physician and principal investigator (PI)Xx_NEWLINE_xXSubject has adequate organ function as determined by the following laboratory values:Xx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate hematologic and organ function as confirmed by laboratory valuesXx_NEWLINE_xXThe participant has adequate hematologic, organ, and coagulation function within 2 weeks (14 days) prior to enrollment (Phase 1b) or randomization (Phase 2).Xx_NEWLINE_xXAdequate hematologic and end-organ functionXx_NEWLINE_xX-  Has adequate organ function.Xx_NEWLINE_xXDemonstrate adequate organ function obtained within 14 days prior to randomization and analyzed by the central laboratory.Xx_NEWLINE_xXDemonstrate adequate organ functionXx_NEWLINE_xXThe participant has adequate hematologic, organ, and coagulation function ?2 weeks (14 days) prior to first dose of study drug:Xx_NEWLINE_xXAdequate organ function as defined by the following criteria:Xx_NEWLINE_xXAdequate hematologic and organ function as confirmed by laboratory valuesXx_NEWLINE_xXAdequate organ system function.Xx_NEWLINE_xXMust have adequate organ function defined as:Xx_NEWLINE_xXAdequate haematologic and end-organ functionXx_NEWLINE_xXHave adequate organ function.Xx_NEWLINE_xXAdequate hematologic and end-organ functionXx_NEWLINE_xXAdequate organ function per protocol-defined criteria.Xx_NEWLINE_xXEvidence of insufficient organ function as determined by the protocol.Xx_NEWLINE_xXAdequate organ function as appropriate for the disease under study. All screening laboratory tests should be performed within 10 days of treatment initiation.Xx_NEWLINE_xXAdequate organ and marrow functionXx_NEWLINE_xXHave adequate hematologic, organ and coagulation function within 2 weeks (14 days) prior to enrollment.Xx_NEWLINE_xXCandidate for pembrolizumab (as determined by physician, and adequate organ function)Xx_NEWLINE_xXAdequate organ function and blood cell counts.Xx_NEWLINE_xXAdequate organ function.Xx_NEWLINE_xXHave adequate organ function (all screening labs should be performed within 15 days prior to study treatment):Xx_NEWLINE_xXHEALTHY SUBJECT: Have adequate organ functionXx_NEWLINE_xXDemonstrate adequate organ function, all screening labs should be performed within 14 days prior to registrationXx_NEWLINE_xXAdequate organ function, hematologic status, coagulation status, kidney function, and liver function as follows:Xx_NEWLINE_xXAdequate organ function.Xx_NEWLINE_xXAdequate organ function confirmed at Screening and within 10 days of initiating treatment, as evidenced by:Xx_NEWLINE_xXAdequate organ function as defined by the following criteria:Xx_NEWLINE_xXAdequate organ function within 14 days of study registrationXx_NEWLINE_xXAdequate hematologic and organ functionXx_NEWLINE_xXPatients must have adequate organ and marrow function as determined by the treating oncologistXx_NEWLINE_xXMust have adequate organ function, as defined by the following:Xx_NEWLINE_xXAdequate organ function.Xx_NEWLINE_xXPatient has adequate organ function at BaselineXx_NEWLINE_xXAdequate organ function as defined by:Xx_NEWLINE_xXAdequate organ and neurologic functionXx_NEWLINE_xXHas adequate organ function including:Xx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate organ function within 28 days prior to enrollment, as defined by the following criteria:Xx_NEWLINE_xXSubjects must have adequate organ and marrow at screening as defined below:Xx_NEWLINE_xXHave adequate organ function.Xx_NEWLINE_xXDemonstrate adequate organ function; all screening laboratory tests should be performed within 7 days of treatment initiationXx_NEWLINE_xXThe patient has adequate organ and marrow function per protocolXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate organ function as defined below:Xx_NEWLINE_xXAdequate organ function as defined below:Xx_NEWLINE_xXHave adequate organ function.Xx_NEWLINE_xXPotentially eligible for reduced intensity conditioning based on known organ function (formal organ function testing may occur after consent)Xx_NEWLINE_xXHave adequate organ function.Xx_NEWLINE_xXAdequate organ and marrow functionXx_NEWLINE_xXDemonstrate adequate organ function, all screening labs should be performed within 10 days of study drug administrationXx_NEWLINE_xXPatients who have received organ transplantations.Xx_NEWLINE_xXAdequate organ function as defined by all the following criteria:Xx_NEWLINE_xXPatients must have adequate organ function at baseline as defined below: • Adequate liver function (within 7 days of crenolanib commencement), as determined by:Xx_NEWLINE_xXAdequate hematologic and end organ function obtained within 2 weeks prior to first dose of study drugXx_NEWLINE_xXPatient has adequate organ function, as indicated by the following laboratory valuesXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate organ functionsXx_NEWLINE_xXAdequate organ function as defined by the following criteria:Xx_NEWLINE_xXOrgan function:Xx_NEWLINE_xXPatients must have adequate organ functionXx_NEWLINE_xXAdequate organ function within 14 days of registrationXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate organ function as determined by the following laboratory values:Xx_NEWLINE_xXAdequate other organ functionsXx_NEWLINE_xXAcceptable end-organ function, except for documented exclusions for organ function compromise due to ALL itselfXx_NEWLINE_xXAdequate organ function as indicated by the following laboratory values. All laboratory tests must be obtained within 7 days prior to the first dose of study treatment:Xx_NEWLINE_xXAdequate organ function as defined below: • Liver function: a. Total bilirubin < 2.0 mg/dL (34 µmol/L) b. AST and/or ALT <3 x ULNXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate normal organ and marrow functionXx_NEWLINE_xXAdequate organ and marrow function as determined by medical oncology evaluationXx_NEWLINE_xXAll patients must have adequate organ function defined as:Xx_NEWLINE_xXOrgan Function Requirements:Xx_NEWLINE_xXAdequate organ function as outlined below (unless due to leukemia)Xx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate organ function including:Xx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAll organ function testing should be done within 28 days of study registrationXx_NEWLINE_xXAdequate organ and marrow functionXx_NEWLINE_xXHave adequate organ function.Xx_NEWLINE_xXInadequate performance status/ organ functionXx_NEWLINE_xXInadequate organ function, evidenced by the following laboratory results:Xx_NEWLINE_xXAdequate organ function.Xx_NEWLINE_xXAdequate End organ functionXx_NEWLINE_xXHas adequate organ function as defined by:Xx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXPatient has adequate organ functionXx_NEWLINE_xXPatients must have adequate organ functionXx_NEWLINE_xXAdequate normal organ and marrow function as defined below (must be done within 30 days prior to enrolment):Xx_NEWLINE_xXAdequate organ system function within 14 days of baseline:Xx_NEWLINE_xXPoor organ function.Xx_NEWLINE_xXAdequate organ and marrow functionXx_NEWLINE_xXHas adequate organ functionXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate organ function as defined in the protocolXx_NEWLINE_xXPatients must have normal organ function as defined below:Xx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXOther serious co-morbid illness or compromised organ functionXx_NEWLINE_xXOrgan function characterized by ? Grade 1Xx_NEWLINE_xXHas adequate organ function as defined by the following criteria:Xx_NEWLINE_xXHave adequate organ functionXx_NEWLINE_xXPatients must have normal organ function as defined below:Xx_NEWLINE_xXAdequate non-hematologic organ system function, defined by:Xx_NEWLINE_xXPatients must have adequate organ and system function.Xx_NEWLINE_xXSubjects who have adequate organ functionsXx_NEWLINE_xXOrgan function must be adequate as follows:Xx_NEWLINE_xXAdequate organ system functions as defined by the laboratory assessments.Xx_NEWLINE_xXhave inadequate organ function per protocolXx_NEWLINE_xXHas adequate organ functionXx_NEWLINE_xXAdequate organ function.Xx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate organ and marrow function, defined per protocolXx_NEWLINE_xXPatient must meet the organ function and system function requirements as stated in the protocolXx_NEWLINE_xXHave adequate organ function defined by the protocol.:Xx_NEWLINE_xXAdequate organ function as evidenced by:Xx_NEWLINE_xXAdequate hematologic and end organ functionXx_NEWLINE_xXAdequate organ function as determined by following laboratory parameters:Xx_NEWLINE_xXAdequate end-organ functionXx_NEWLINE_xXAdequate end-organ function, as determined by laboratory tests obtained within 28 days prior to the first dose of study drugXx_NEWLINE_xXPatients must have organ function as defined below:Xx_NEWLINE_xXAcceptable organ and marrow function during the Screening Period as defined by the\n             protocol.Xx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate hematologic and end-organ functionXx_NEWLINE_xXAdequate hematologic and organ function as confirmed by laboratory valuesXx_NEWLINE_xX-  The participant has adequate organ function:Xx_NEWLINE_xXAdequate organ function as defined by study-specific laboratory testsXx_NEWLINE_xXDemonstrates adequate organ function.Xx_NEWLINE_xXAdequate organ function, as defined by the following criteria:Xx_NEWLINE_xXAdequate organ function.Xx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate hematological and organ function, confirmed by lab valuesXx_NEWLINE_xXAdequate organ function per protocol-defined criteria.Xx_NEWLINE_xXDemonstrates adequate organ function.Xx_NEWLINE_xXadequate organ functionXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate organ function defined as:Xx_NEWLINE_xXAdequate hematologic and end-organ function.Xx_NEWLINE_xXAdequate hematological and organ function as confirmed by laboratory valuesXx_NEWLINE_xXAdequate organ function:Xx_NEWLINE_xXInadequate organ function including:Xx_NEWLINE_xXAdequate hematologic and end organ functionXx_NEWLINE_xXAcceptable organ function, as evidenced by the following laboratory data:Xx_NEWLINE_xXAdequate organ function prior to registrationXx_NEWLINE_xXAdequate hematologic and organ function within 28 days prior to initiation of study treatmentXx_NEWLINE_xXAdequate hematologic and end-organ function test resultsXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXDemonstrates adequate organ functionXx_NEWLINE_xXAcceptable laboratory parameters and adequate organ reserve.Xx_NEWLINE_xXDemonstrates adequate organ function.Xx_NEWLINE_xXAdequate organ function defined as follows:Xx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXHas adequate organ functionXx_NEWLINE_xXAdequate organ and marrow functionXx_NEWLINE_xXHave adequate organ function.Xx_NEWLINE_xXHas adequate organ function as defined by protocol defined labs.Xx_NEWLINE_xXAdequate organ function as shown by:Xx_NEWLINE_xXAdequate organ function defined as:Xx_NEWLINE_xXAdequate hematologic and end organ functionXx_NEWLINE_xXHemodynamically stable and adequate organ functionXx_NEWLINE_xXPoor organ function.Xx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXInadequate organ function including:Xx_NEWLINE_xXAdequate organ and marrow functionXx_NEWLINE_xXAdequate major organ function (normal or minimal alteration in liver, kidney, hematological, metabolic and cardiac function)Xx_NEWLINE_xXAdequate organ function.Xx_NEWLINE_xXDemonstrates adequate organ function.Xx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate hematologic and end organ function, confirmed by laboratory results obtained within 28 days prior to initiation of study drugXx_NEWLINE_xXInadequate organ function including:Xx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate hematologic and end-organ functionXx_NEWLINE_xXAdequate organ function as defined in the protocolXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXChemistry panel obtained 30 days prior to registration on study, with adequate organ functionXx_NEWLINE_xXHave adequate organ function.Xx_NEWLINE_xXAdequate hematologic and end organ functionXx_NEWLINE_xXAdequate hematologic and end organ functionXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate hematologic and organ function as confirmed by laboratory valuesXx_NEWLINE_xXAdequate organ function at baseline as defined below. All laboratory assessments should be performed within 10 days of treatment initiation.Xx_NEWLINE_xXAdequate hematologic and end organ functionXx_NEWLINE_xXHave adequate organ function, as defined by the study protocol.Xx_NEWLINE_xXSubject must have adequate organ function as indicated by the following laboratory values in the table below:Xx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXHas adequate organ function.Xx_NEWLINE_xXAdequate hematologic and end-organ function within 28 days prior to treatment initiationXx_NEWLINE_xXSubjects must have adequate organ and marrow function as defined below:Xx_NEWLINE_xXHave organ and marrow function at the screening and pre-dose visits as defined by:Xx_NEWLINE_xXPatients must have adequate organ function:Xx_NEWLINE_xXAdequate organ function as defined by the following criteria:Xx_NEWLINE_xXPatients must have normal organ and marrow function as defined below:Xx_NEWLINE_xXAdequate Organ FunctionXx_NEWLINE_xXAdequate organ function per protocol-defined criteria.Xx_NEWLINE_xXAdequate organ function per protocol-defined criteria.Xx_NEWLINE_xXAdequate organ function per protocol-defined criteria.Xx_NEWLINE_xXAdequate organ and marrow functionXx_NEWLINE_xXAdequate organ function defined as follows:Xx_NEWLINE_xXAdequate hematologic and end-organ functionXx_NEWLINE_xXhave adequate organ functionXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXHave adequate organ function.Xx_NEWLINE_xXDemonstrates adequate organ functionXx_NEWLINE_xXHas adequate organ functionXx_NEWLINE_xXAdequate organ function as defined below:Xx_NEWLINE_xXOrgan FunctionXx_NEWLINE_xXPatients must have normal organ and marrow function documented within 7 days of study enrollment as defined below:Xx_NEWLINE_xXInadequate organ functionXx_NEWLINE_xXDemonstrate adequate organ function as detailed aboveXx_NEWLINE_xXAdequate hematologic and end organ functionXx_NEWLINE_xXSubjects must have adequate organ function as indicated by the following laboratory values.Xx_NEWLINE_xXHave adequate organ functions.Xx_NEWLINE_xXAdequate hematologic and end organ functionXx_NEWLINE_xXHave adequate organ function.Xx_NEWLINE_xXAdequate organ and marrow functionXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXHave adequate organ functionXx_NEWLINE_xXAdequate baseline organ function.Xx_NEWLINE_xXAdequate hematologic and organ function within 14 days before the first study treatmentXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXHave adequate organ function including:Xx_NEWLINE_xXHave adequate organ functionXx_NEWLINE_xXHas adequate organ function as defined by protocolXx_NEWLINE_xXAdequate organ and marrow function, resolution of all toxic effects of prior therapy or surgical proceduresXx_NEWLINE_xXAdequate organ and marrow functionXx_NEWLINE_xXOrgan Function Requirements - Subjects must have adequate organ functions as defined below:Xx_NEWLINE_xXAdequate hematologic and end organ function, defined by the following laboratory results obtained within 14 days prior to the first study treatment (Cycle 1, Day 1):Xx_NEWLINE_xXSubject has adequate organ function as determined by the following laboratory values:Xx_NEWLINE_xXAdequate organ function defined as:Xx_NEWLINE_xXAcceptable laboratory parameters and adequate organ reserve.Xx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXHave adequate organ function, with all screening labs performed within 7 days of treatment initiation.Xx_NEWLINE_xXHave adequate organ function.Xx_NEWLINE_xXAdequate organ function defined as follows: System and Laboratory Values: HematologicXx_NEWLINE_xXHas adequate organ functionXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXParticipant has adequate organ functions, evidenced by the following:Xx_NEWLINE_xXAdequate organ function including:Xx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXDemonstrate adequate organ function, all screening labs should be performed within 14 days of treatment initiationXx_NEWLINE_xXAdequate organ function.Xx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXThe participant has adequate organ function.Xx_NEWLINE_xXThe participant has adequate organ function, including:Xx_NEWLINE_xXDemonstrate adequate organ function, all screening labs should be performed within 6 weeks of treatment initiationXx_NEWLINE_xXSubject has adequate organ function.Xx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate organ and marrow function; Evidence of post-menopausal status or negative urinary or serum pregnancy test.Xx_NEWLINE_xXAdequate hematologic and end organ functionXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate baseline organ function as defined belowXx_NEWLINE_xXAdequate organ and marrow functionXx_NEWLINE_xXAdequate hematologic and end organ function Cohort 2-Specific Inclusion CriteriaXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXHave adequate organ and hematologic function, as determined by:Xx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate organ function including:Xx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate hematologic and end organ functionXx_NEWLINE_xXAdequate organ and marrow function , as defined below:Xx_NEWLINE_xXAdequate organ function within 14 days of dosingXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate hematologic and end-organ functionXx_NEWLINE_xXHas adequate organ functionXx_NEWLINE_xXAdequate organ functionsXx_NEWLINE_xXAdequate organ function, defined as:Xx_NEWLINE_xXAdequate organ function according to protocol-defined criteriaXx_NEWLINE_xXInadequate organ function as describedXx_NEWLINE_xXAdequate major organ system functionXx_NEWLINE_xXAdequate organ function including:Xx_NEWLINE_xXAdequate organ function including:Xx_NEWLINE_xXHave adequate organ function;Xx_NEWLINE_xXAdequate end organ function as defined by:Xx_NEWLINE_xXAdequate organ and marrow function.Xx_NEWLINE_xXHave adequate organ function as defined by specified laboratory valuesXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXPatients must have normal organ and marrow function as defined below:Xx_NEWLINE_xXPatients must have adequate hematologic and organ function.Xx_NEWLINE_xXAdequate baseline organ functionXx_NEWLINE_xXHave adequate organ system functionXx_NEWLINE_xXAdequate organ function as defined by the following criteria:Xx_NEWLINE_xXPatients with adequate organ function as measured by:Xx_NEWLINE_xXAdequate hematologic and end organ functionXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXHas adequate organ functionXx_NEWLINE_xXAdequate organ and marrow function.Xx_NEWLINE_xXThe participant has adequate organ function.Xx_NEWLINE_xXAdequate organ function as evidenced by the following laboratory findings:Xx_NEWLINE_xXAdequate organ function within 10 days of Day 1Xx_NEWLINE_xXHas adequate organ functionXx_NEWLINE_xXDemonstrates adequate organ function.Xx_NEWLINE_xXAdequate baseline organ function.Xx_NEWLINE_xXHave adequate organ function (all screening labs should be performed within 15 days prior to treatment initiation):Xx_NEWLINE_xXAdequate organ function within 3 weeks prior to first study drug administration as evidenced by:Xx_NEWLINE_xXAdequate organ function per blood workXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXPatients must have adequate organ function as indicated by the following laboratory values:Xx_NEWLINE_xXAdequate organ function defined as follows:Xx_NEWLINE_xXOther serious co-morbid illness or compromised organ functionXx_NEWLINE_xXAcceptable hematologic and organ functionXx_NEWLINE_xXPatient must meet the organ function requirements as stated in the protocol.Xx_NEWLINE_xXAdequate organ function as shown by:Xx_NEWLINE_xXAdequate baseline organ functionXx_NEWLINE_xXAdequate hematologic and end organ function, defined by the following laboratory results obtained within 14 days prior to the first study treatment (Cycle 1, Day 1)Xx_NEWLINE_xXHave adequate organ functionXx_NEWLINE_xXPatients must have adequate organ and marrow function as defined belowXx_NEWLINE_xXThe participant has adequate organ and blood cell countsXx_NEWLINE_xXAdequate organ function and baseline laboratory valuesXx_NEWLINE_xXSubject has adequate organ function.Xx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate organ function defined as follows:Xx_NEWLINE_xXAdequate organ function.Xx_NEWLINE_xXAdequate organ function including:Xx_NEWLINE_xXHas adequate organ function, before the first dose of study drug.Xx_NEWLINE_xXAdequate organ function.Xx_NEWLINE_xXAdequate organ function including the following:Xx_NEWLINE_xXAdequate organ function defined as follows:Xx_NEWLINE_xXSerious organ dysfunctionXx_NEWLINE_xXAdequate organ function defined as:Xx_NEWLINE_xXAdequate organ function defined as follows:Xx_NEWLINE_xXAdequate organ and marrow functionXx_NEWLINE_xXAdequate organ and hematological function as evidenced by the following laboratory values within 14 days before enrollment:Xx_NEWLINE_xXAdequate organ and hematological function as evidenced by the following laboratory values within 14 days before enrollment:Xx_NEWLINE_xXAdequate organ function defined as follows:Xx_NEWLINE_xXAdequate organ system function.Xx_NEWLINE_xXPatients must have normal organ and marrow function as defined below:Xx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate hematologic and end-organ functionXx_NEWLINE_xXDemonstrate adequate organ function.Xx_NEWLINE_xXAdequate organ and marrow functionXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAcceptable organ and marrow function ?21 days prior to registration:Xx_NEWLINE_xXAdequate hematologic and end-organ functionXx_NEWLINE_xXAcceptable organ function as evidenced by the following:Xx_NEWLINE_xXAdequate organ function.Xx_NEWLINE_xXAdequate hematologic and organ function within 14 days before the first study treatmentXx_NEWLINE_xXAdequate organ and marrow functionXx_NEWLINE_xXHave adequate organ function.Xx_NEWLINE_xXHave adequate organ function.Xx_NEWLINE_xXAdequate hematologic and end organ functionXx_NEWLINE_xXHave adequate organ function.Xx_NEWLINE_xXAdequate hematologic and end-organ functionXx_NEWLINE_xXAdequate organ function as defined below:Xx_NEWLINE_xXAdequate hematologic and end-organ functionXx_NEWLINE_xXAdequate hematologic and end-organ functionXx_NEWLINE_xXAdequate organ function as determined by the following laboratory results, within 28\n             days prior to randomizationXx_NEWLINE_xXAdequate hematologic and organ function as confirmed by laboratory values at Screening:Xx_NEWLINE_xXAdequate hematologic and end-organ functionXx_NEWLINE_xXAdequate organ and marrow functionXx_NEWLINE_xXPatients must have normal organ and hematologic function therapyXx_NEWLINE_xXPatients must have normal organ and marrow function as defined below:Xx_NEWLINE_xXAdequate organ function defined as follows:Xx_NEWLINE_xXAdequate organ function defined as below:Xx_NEWLINE_xXAdequate organ function within 14 days of study entryXx_NEWLINE_xXAdequate organ and marrow functionXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate organ function at baseline:Xx_NEWLINE_xXHave adequate organ function.Xx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXMust have normal organ and marrow function reported within 14 days prior to randomizationXx_NEWLINE_xXAdequate organ function, including the following:Xx_NEWLINE_xXAdequate hematologic and end-organ functionXx_NEWLINE_xXAdequate baseline organ function as defined in the protocol.Xx_NEWLINE_xXAdequate organ and marrow functionXx_NEWLINE_xXAdequate organ function as defined below:Xx_NEWLINE_xXFor all tumor types, adequate organ and marrow function, as defined below:Xx_NEWLINE_xXHave adequate organ function as defined by specified laboratory valuesXx_NEWLINE_xXInadequate organ function as defined on laboratory testsXx_NEWLINE_xXMust have adequate organ function as defined by the following screening values (Retesting of borderline screening organ function and treatment with blood transfusions, growth factors etc. will be allowed):Xx_NEWLINE_xXAdequate bone morrow and organ functionXx_NEWLINE_xXAdequate hematologic and end-organ functionXx_NEWLINE_xXAdequate hematologic and end-organ functionXx_NEWLINE_xXThe subject has poor organ and marrow function as defined in the protocol.Xx_NEWLINE_xXInadequate hematologic, biochemical, and organ functionXx_NEWLINE_xXAdequate hematologic and end organ functionXx_NEWLINE_xXAdequate organ function:Xx_NEWLINE_xXPreviously treated; NOTE: no limit to prior therapy provided there is adequate residual organ functionXx_NEWLINE_xXPatients must have adequate organ function, as defined by the following parameterXx_NEWLINE_xXSubject must have normal organ and marrow function as defined below:Xx_NEWLINE_xXSubject's laboratory results indicate inadequate organ functionXx_NEWLINE_xXAdequate organ function including:Xx_NEWLINE_xXAdequate residual organ function per treating physician discretion; Note: there is no limit with regard to the number of prior therapiesXx_NEWLINE_xXPatients must have normal organ and marrow function as defined below:Xx_NEWLINE_xXPatients must have normal organ and marrow functionXx_NEWLINE_xXAdequate baseline organ function.Xx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate hematologic and organ function within 14 days prior to treatment initiationXx_NEWLINE_xXAdequate hematologic and end-organ functionXx_NEWLINE_xXAdequate organ function as defined by:Xx_NEWLINE_xXAdequate organ and marrow function:Xx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXOrgan function </= grade 1.Xx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate hematologic and end organ functionXx_NEWLINE_xXAdequate organ and marrow functionXx_NEWLINE_xXInadequate hematological, biochemical or organ functionXx_NEWLINE_xXAdequate organ function;Xx_NEWLINE_xXAdequate hematologic and end-organ functionXx_NEWLINE_xXHave adequate organ function as defined by specified laboratory valuesXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate organ system function determined within 14 days prior to first dose of study treatment.Xx_NEWLINE_xXAdequate organ function.Xx_NEWLINE_xXAt the time of the CMV specific T cell infusion, the recipient must have adequate organ function as indicated by < grade 3 across all organ systems except for hematologic toxicityXx_NEWLINE_xXAdequate organ and marrow functionXx_NEWLINE_xXPatients must have adequate organ function, as defined by the following parameters:Xx_NEWLINE_xXHave adequate organ function, including:Xx_NEWLINE_xXAdequate organ function.Xx_NEWLINE_xXAdequate organ system function.Xx_NEWLINE_xXNormal organ function tests including CreatinineXx_NEWLINE_xXNormal organ function tests including BilirubinXx_NEWLINE_xXNormal organ and marrow function.Xx_NEWLINE_xXOther serious co-morbid illness or compromised organ function.Xx_NEWLINE_xXPatients with adequate organ function as measured by:Xx_NEWLINE_xXAdequate hematologic and end-organ functionXx_NEWLINE_xXPatients must have adequate organ function within 14 days prior to registration, as defined below:Xx_NEWLINE_xXAdequate hematologic and end organ functionXx_NEWLINE_xXHas adequate organ function as determined by laboratory testsXx_NEWLINE_xXadequate organ functionXx_NEWLINE_xXAdequate organ function, including the following:Xx_NEWLINE_xXAdequate hematologic and organ function, including blood counts, liver and kidney function Stage I Arm A (GDC-0077):Xx_NEWLINE_xXAdequate other organ function at screening and enrollment.Xx_NEWLINE_xXAdequate other organ function at screening and enrollment.Xx_NEWLINE_xXSubject must have adequate organ function as indicated by the laboratory values below:Xx_NEWLINE_xXParticipants must have adequate organ function, including the following:Xx_NEWLINE_xXPatients are eligible regardless of organ/marrow functionXx_NEWLINE_xXAll organ function testing should be done within 28 days of study registrationXx_NEWLINE_xXParticipants must have adequate organ and marrow function to proceed to transplantXx_NEWLINE_xXRegarding non-hematologic organ function, no specific criteria for non-hematologic organ function are specified; however, if moderate-to-severe (major) organ function is present, such should be discussed with the PI, as various degrees of non-hematologic organ dysfunction may compromise either (or both) toxicity and response evaluations; also, if there is concern regarding potential reversibility of any specific organ dysfunction, this issue should also be addressed by consultation with an appropriate sub-specialistXx_NEWLINE_xXAdequate hematologic and end organ functionXx_NEWLINE_xXAdequate hematologic, cardiac, and end-organ functionXx_NEWLINE_xXAcceptable laboratory parameters and adequate organ reserve.Xx_NEWLINE_xXAdequate organ and marrow function.Xx_NEWLINE_xXAdequate hematologic and end-organ functionXx_NEWLINE_xXNo organ and marrow function requirementsXx_NEWLINE_xXAdequate organ function, as defined by the following criteria (per central or local laboratory values):Xx_NEWLINE_xXNo restrictions will be made based on organ or marrow functionXx_NEWLINE_xXPatients must have adequate organ functions at the time of registration:Xx_NEWLINE_xXAdequate organ function as determined by the following laboratory values:Xx_NEWLINE_xXOrgan Function Requirements: Subjects must have adequate liver function as defined by:Xx_NEWLINE_xXNormal organ and marrow functionXx_NEWLINE_xXOrgan Function Requirements: Subjects must have adequate liver function as defined by:Xx_NEWLINE_xXAdequate hematologic and end-organ functionXx_NEWLINE_xXAcceptable pre-study organ function during screening defined as:Xx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXAdequate organ function including:Xx_NEWLINE_xXRequirements for organ and marrow function are not applicable to this study, but function will need to be sufficient to undergo planned therapyXx_NEWLINE_xXNo requirements for organ and marrow functionXx_NEWLINE_xXHas adequate organ function.Xx_NEWLINE_xXSubject must have adequate organ function as defined in the protocol.Xx_NEWLINE_xXAcceptable laboratory parameters and adequate organ reserve.Xx_NEWLINE_xXHas adequate organ functionXx_NEWLINE_xXAdequate organ function including:Xx_NEWLINE_xXAdequate baseline organ function:Xx_NEWLINE_xXHave adequate organ functionXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXNormal organ and marrow function within limits as defined below:Xx_NEWLINE_xXOrgan function requirements:Xx_NEWLINE_xXAdequate organ function determined within 14 days prior to enrollmentXx_NEWLINE_xXThe patient has adequate organ and marrow function as follows:Xx_NEWLINE_xXAdequate end organ function as defined by:Xx_NEWLINE_xXAdequate organ function.Xx_NEWLINE_xXSubjects must have normal organ and marrow function as defined below:Xx_NEWLINE_xXAdequate hematologic and end organ functionXx_NEWLINE_xXMust have adequate organ function, including the following:Xx_NEWLINE_xXAdequate organ function as determined by the investigatorXx_NEWLINE_xXSubjects must have normal organ and marrow function as defined below:Xx_NEWLINE_xXAdequate organ and marrow functionXx_NEWLINE_xXAdequate organ function within 7 days prior to enrollment, as defined by the following criteria:Xx_NEWLINE_xXDemonstrates adequate organ function, within 10 days prior to the start of study drug.Xx_NEWLINE_xXAdequate hematologic and end-organ functionXx_NEWLINE_xXAdequate organ system function, defined as follows:Xx_NEWLINE_xXAdequate organ function as per protocol.Xx_NEWLINE_xXHas adequate organ functionXx_NEWLINE_xXAdequate organ functionXx_NEWLINE_xXEvidence of adequate organ function by standard laboratory tests.Xx_NEWLINE_xX